Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cedna Biotech is a biotechnology company headquartered in Suzhou, China, specializing in the development of circular RNA (circRNA) therapeutics and vaccines. The company leverages its proprietary circRNA platform to create stable, long-lasting, and low-immunogenicity treatments for a variety of conditions, including oncology, infectious diseases, and rare genetic disorders. By utilizing circularized RNA structures, Cedna aims to overcome the stability and expression limitations associated with traditional linear mRNA. The company is currently in the pre-clinical stage, advancing a pipeline of candidates supported by advanced lipid nanoparticle (LNP) delivery systems. Cedna is backed by prominent investors such as Qiming Venture Partners and Lilly Asia Ventures. Their mission is to pioneer the next generation of RNA-based medicine to address significant unmet medical needs globally.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Cedna Biotech.